Collegium Pharmaceutical Inc.

23.27-0.1900-0.81%Vol 178.72K1Y Perf 22.87%
Apr 16th, 2021 16:00 DELAYED
BID21.86 ASK24.99
Open23.67 Previous Close23.46
Pre-Market- After-Market23.27
 - -  - -%
Target Price
31.13 
Analyst Rating
Strong Buy 1.30
Potential %
33.78 
Finscreener Ranking
★★★+     53.30
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
★★+     48.83
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
★★★★★     69.68
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
 —    -
Market Cap819.20M 
Earnings Rating
Strong Sell
Price Range Ratio 52W %
67.64 
Earnings Date
6th May 2021

Today's Price Range

22.8323.67

52W Range

15.6626.91

5 Year PE Ratio Range

-19.40-5.40

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Sell
Performance
1 Week
-0.26%
1 Month
-8.31%
3 Months
-3.28%
6 Months
12.14%
1 Year
22.87%
3 Years
-6.17%
5 Years
25.51%
10 Years
-

TickerPriceChg.Chg.%
COLL23.27-0.1900-0.81
AAPL134.16-0.3400-0.25
GOOG2 297.761.10000.05
MSFT260.741.24000.48
XOM56.66-0.3200-0.56
WFC43.841.60003.79
JNJ162.241.85001.15
FB306.18-1.6400-0.53
GE13.39-0.1600-1.18
JPM153.301.13000.74
Financial StrengthValueIndustryS&P 500US Markets
1.10
1.20
0.54
1.43
2.00
Leverage Ratio 3.80
ProfitabilityValueIndustryS&P 500US Markets
58.00
12.80
28.50
-1 156.00
11.66
RevenueValueIndustryS&P 500US Markets
233.51M
6.63
45.72
-
Earnings HistoryEstimateReportedSurprise %
Q04 20200.290.20-31.03
Q03 20200.230.3239.13
Q02 20200.240.23-4.17
Q01 20200.320.01-96.88
Q04 2019-0.17-0.0758.82
Q03 2019-0.16-0.18-12.50
Q02 2019-0.19-0.1426.32
Q01 2019-0.30-0.293.33
Earnings Per EndEstimateRevision %Trend
3/2021 QR0.29-21.62Negative
6/2021 QR0.38-2.56Negative
12/2021 FY1.64-1.80Negative
12/2022 FY2.472.49Positive
Next Report Date6th May 2021
Estimated EPS Next Report0.29
Estimates Count3
EPS Growth Next 5 Years %20.00
Volume Overview
Volume178.72K
Shares Outstanding35.20M
Trades Count2.70K
Dollar Volume16.11M
Avg. Volume559.76K
Avg. Weekly Volume203.26K
Avg. Monthly Volume277.94K
Avg. Quarterly Volume582.29K

Collegium Pharmaceutical Inc. (NASDAQ: COLL) stock closed at 23.27 per share at the end of the most recent trading day (a -0.81% change compared to the prior day closing price) with a volume of 179.88K shares and market capitalization of 819.20M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 234 people. Collegium Pharmaceutical Inc. CEO is Joseph J. Ciaffoni.

The one-year performance of Collegium Pharmaceutical Inc. stock is 22.87%, while year-to-date (YTD) performance is 16.18%. COLL stock has a five-year performance of 25.51%. Its 52-week range is between 15.66 and 26.91, which gives COLL stock a 52-week price range ratio of 67.64%

Collegium Pharmaceutical Inc. currently has a PE ratio of 30.30, a price-to-book (PB) ratio of 4.36, a price-to-sale (PS) ratio of 3.44, a price to cashflow ratio of 8.60, a PEG ratio of 2.32, a ROA of 5.47%, a ROC of 11.79% and a ROE of 19.03%. The company’s profit margin is 11.66%, its EBITDA margin is 28.50%, and its revenue ttm is $233.50 Million , which makes it $6.63 revenue per share.

Of the last four earnings reports from Collegium Pharmaceutical Inc., there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $0.29 for the next earnings report. Collegium Pharmaceutical Inc.’s next earnings report date is 06th May 2021.

The consensus rating of Wall Street analysts for Collegium Pharmaceutical Inc. is Strong Buy (1.3), with a target price of $31.13, which is +33.78% compared to the current price. The earnings rating for Collegium Pharmaceutical Inc. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Collegium Pharmaceutical Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Collegium Pharmaceutical Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 11.17, ATR14 : 1.26, CCI20 : -60.77, Chaikin Money Flow : -0.07, MACD : -0.12, Money Flow Index : 52.02, ROC : -2.39, RSI : 51.15, STOCH (14,3) : 40.34, STOCH RSI : 0.33, UO : 48.87, Williams %R : -59.66), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Collegium Pharmaceutical Inc. in the last 12-months were: Alison B. Fleming (Option Excercise at a value of $275 040), Alison B. Fleming (Sold 23 967 shares of value $519 441 ), Joseph Ciaffoni (Option Excercise at a value of $932 444), Joseph Ciaffoni (Sold 141 305 shares of value $3 110 191 ), Michael T. Heffernan (Sold 114 725 shares of value $2 599 712 ), Scott Dreyer (Option Excercise at a value of $127 200), Scott Dreyer (Sold 23 083 shares of value $545 953 ), Shirley R. Kuhlmann (Sold 13 141 shares of value $295 670 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
8 (80.00 %)
8 (88.89 %)
8 (88.89 %)
Moderate Buy
1 (10.00 %)
1 (11.11 %)
1 (11.11 %)
Hold
1 (10.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.30
Strong Buy
1.11
Strong Buy
1.11

Collegium Pharmaceutical Inc.

Collegium Pharmaceutical Inc is a specialty pharmaceutical company. It is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods including chewing, crushing and dissolving. Its product Xtampza ER, is an abuse-deterrent, extended-release, oral formulation of oxycodone.

CEO: Joseph J. Ciaffoni

Telephone: +1 781 713-3699

Address: 100 Technology Center Drive, Stoughton 02072, MA, US

Number of employees: 234

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

46%54%

Bearish Bullish

40%60%

Bearish Bullish

55%45%

News

Stocktwits